METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Clinical trials for METASTATIC TRIPLE-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC TRIPLE-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for METASTATIC TRIPLE-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to shrink tough breast cancer
Disease control OngoingThis study tests two experimental drugs (AK117 and AK112) plus chemotherapy in 120 people with advanced triple-negative breast cancer that hasn't been treated yet. The goal is to see if the combination shrinks tumors and is safe. Participants must have a specific type of breast c…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated May 26, 2026 05:52 UTC
-
New cocktail aims to tame tough breast cancer
Disease control OngoingThis study tests a four-drug combination (trilaciclib, pembrolizumab, gemcitabine, and carboplatin) in people with advanced triple-negative breast cancer that cannot be removed by surgery or has spread. The goal is to see how well the treatment shrinks tumors and how safe it is. …
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated May 26, 2026 05:44 UTC
-
Promising drug targets Hard-to-Treat breast cancer in chinese patients
Disease control OngoingThis study tests a drug called sacituzumab govitecan in 80 Chinese patients with metastatic triple-negative breast cancer who have already tried at least two other treatments. The goal is to see if the drug can shrink tumors or slow the disease. This is a phase 2 trial, meaning i…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
New combo therapy shows promise for Hard-to-Treat breast cancer
Disease control OngoingThis study tested whether adding another targeted drug (ceralasertib or adavosertib) to olaparib works better than olaparib alone for people with metastatic triple-negative breast cancer. Participants had specific gene changes (HRR-related, including BRCA). The trial aimed to see…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 18, 2026 12:03 UTC